Login to Your Account



Financings Roundup

Beyond Kalbitor: Dyax Adds $30M for HAE Prophylactic

By Jennifer Boggs
Managing Editor

Tuesday, May 14, 2013
Dyax Corp. is more than doubling its cash position with a $30 million registered direct offering, with proceeds to fund R&D activities, namely clinical development of DX-2930, a drug slated to start clinical development for prophylactic use in hereditary angioedema (HAE).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription